Disappointing therapeutics based on the amyloid hypothesis have led Alzheimer’s researchers to explore alternatives, including targeting neuroinflammation, epigenetic alterations and lasers. Meanwhile, with nowhere else to turn, carriers of AD-associated APOE4 scour the internet and trade tips for fighting the disease on their own.
Read about wunderkind and anti-aging funder Laura Deming’s remarkable path from Cynthia Kenyon’s lab to Longevity Fund in this interview from TechCrunch.
Tegan has an eclectic academic background and writes about science and people here and elsewhere on the web.
Article originally posted at